BioAlliance reports Loramyc approval in UK and Denmark

BioAlliance Pharma said that the grant of the marketing authorization in the UK represents an important milestone for the company especially with the payment of E2.5 million by its partner SpePharm, according to the terms of the agreement signed in March 2007, which led to the creation of the SpeBio joint venture for the distribution of Loramyc in Europe.

Dominique Costantini, CEO of BioAlliance, said: “We are delighted of this European success which confirms the quality and the efficiency of our development and regulatory teams and experts. Currently being launched in France, Loramyc will be present on the European market in 2008 as planned. The other main European countries should grant their marketing authorization for Loramyc in the very near future.”